BRISTOL-MYERS SQUIBB COMPANY (NYSE: BMY)

BRISTOL-MYERS SQUIBB COMPANY

NYSE: BMY (Bristol-Myers Squibb Company)

最近更新时间: 27 Jan, 9:18PM

55.56

0.96 (1.76%)

加入群组

前收盘价格	54.60
收盘价格	54.56
成交量	11,334,595
平均成交量 (3个月)	15,178,925
市值	113,106,444,288

市盈率 (P/E TTM)	18.71
预期市盈率 (P/E Forward)	9.38
价格/销量 (P/S)	2.37
股市价格/股市净资产 (P/B)	6.14

52周波幅	42.52 (-23%) — 63.33 (13%)
利润日期	5 Feb 2026
股息率 (DY TTM)	4.84%

市场趋势

		短期	中期
行业	Drug Manufacturers - General (US)	看涨	混合的
	Drug Manufacturers - General (全球的)	看涨	混合的
股票	Bristol-Myers Squibb Company	看涨	看跌

AIStockmoo 评分

-0.3

分析师共识	1.5
内部交易活动	-3.0
价格波动	-3.5
技术平均移动指标	1.5
技术振荡指标	2.0
平均	-0.30

相关股票

股票	市值	DY	P/E（TTM）	P/B
BMY	113 B	4.84%	18.71	6.14
JNJ	573 B	0.52%	21.58	7.08
ABBV	399 B	0.73%	169.65	50.46
MRK	270 B	0.75%	14.29	5.55
PFE	151 B	1.62%	19.48	1.58
GSK	108 B	1.62%	14.65	4.53

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
部门	Healthcare
行业	Drug Manufacturers - General
投资方式	Large Value
内部持股比例	0.07%
机构持股比例	82.11%

52周波幅	42.52 (-23%) — 63.33 (13%)
目标价格波幅	37.00 (-33%) — 66.00 (18%)
高	66.00 (Piper Sandler, 18.79%)	购买
中	60.00 (7.99%)
低	37.00 (Morgan Stanley, -33.41%)	卖出
平均值	58.30 (4.93%)
总计	5 购买, 4 保留, 1 卖出
平均价格@调整类型	53.73

公司	日期	目标价格	调整类型	价格@调整类型
Piper Sandler	28 Jan 2026	66.00 (18.79%)	购买	54.62
Citigroup	27 Jan 2026	60.00 (7.99%)	保留	55.56
Citigroup	07 Jan 2026	53.00 (-4.61%)	保留	56.72
Leerink Partners	13 Jan 2026	60.00 (7.99%)	购买	55.92
Scotiabank	09 Jan 2026	60.00 (7.99%)	保留	55.86
Scotiabank	04 Dec 2025	53.00 (-4.61%)	保留	51.95
UBS	07 Jan 2026	65.00 (16.99%)	购买	56.72
B of A Securities	15 Dec 2025	61.00 (9.79%)	购买	54.29
Guggenheim	12 Dec 2025	62.00 (11.59%)	购买	52.41
Morgan Stanley	12 Dec 2025	37.00 (-33.41%)	卖出	52.41
Wells Fargo	10 Dec 2025	55.00 (-1.01%)	保留	51.21
Goldman Sachs	02 Dec 2025	57.00 (2.59%)	保留	48.25
显示更多

名称	平均购买 ($)	平均卖出 ($)	总净额	总净值 ($)
HICKEY BENJAMIN	-	55.05	-3,810	-209,741
MEYERS GREGORY SCOTT	-	55.05	-833	-45,857
累积净数量				-4,643
累积净值 ($)				-255,597
累积平均购买 ($)				-
累积平均卖出 ($)				55.05

名称	持有人	日期	类型	数量	价格	价值 ($)
HICKEY BENJAMIN	职员	01 Feb 2026	处理 (-)	3,810	55.05	209,741
HICKEY BENJAMIN	职员	01 Feb 2026	执行期权	10,079	-	-
MEYERS GREGORY SCOTT	职员	01 Feb 2026	处理 (-)	833	55.05	45,857
MEYERS GREGORY SCOTT	职员	01 Feb 2026	执行期权	2,543	-	-

日期	类型	细节
05 Feb 2026	公告	Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
04 Feb 2026	公告	Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
03 Feb 2026	公告	Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
20 Jan 2026	公告	Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
20 Jan 2026	CNBC	Drug pricing, patent losses and deals: Here's what pharma execs see ahead in the industry
12 Jan 2026	公告	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
02 Jan 2026	公告	Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference
19 Dec 2025	CNBC	Nine of the largest pharma companies ink deals with Trump to lower drug prices
19 Dec 2025	公告	Bristol Myers Squibb Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for Americans
18 Dec 2025	公告	Bristol Myers Squibb to Report Results for Fourth Quarter 2025 on February 5, 2026
11 Dec 2025	公告	U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
10 Dec 2025	公告	Bristol Myers Squibb Announces Dividend Increase
08 Dec 2025	公告	Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
04 Dec 2025	公告	Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
03 Dec 2025	公告	Terray Therapeutics Achieves AI-Enabled Drug Discovery Milestone in Collaboration with Bristol Myers Squibb
03 Dec 2025	公告	Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
01 Dec 2025	公告	Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
26 Nov 2025	公告	Bristol Myers Squibb to Participate in Citi’s 2025 Global Healthcare Conference
24 Nov 2025	公告	Bristol Myers Squibb to Host Hematology-Focused Investor Event
24 Nov 2025	公告	Bristol Myers Squibb Receives Approval from the European Commission to Expand Use of CAR T Cell Therapy Breyanzi for Relapsed or Refractory Mantle Cell Lymphoma
18 Nov 2025	公告	Bristol Myers Squibb Announces Accepted Amounts and Pricing Terms of its Tender Offers
17 Nov 2025	公告	Bristol Myers Squibb Announces Early Participation Results, Amendment and Early Settlement of Tender Offers
14 Nov 2025	公告	Update on Phase 3 Librexia ACS Trial
12 Nov 2025	公告	Sarah Cannon Research Institute and Bristol Myers Squibb Expand Strategic Collaboration to Accelerate Patient Enrollment and Broaden Access to Innovative Cancer Research
05 Nov 2025	公告	Bristol Myers Squibb Prices €5 Billion of Senior Unsecured Notes
显示更多

股息率 (DY TTM)	4.84%
5年平均股息收益率	3.20%
股息支付比率	91.04%

除息日	公告日期	支付日期	详情
03 Jan 2025	11 Dec 2024	03 Feb 2025	0.62 现金
04 Oct 2024	10 Sep 2024	01 Nov 2024	0.6 现金
05 Jul 2024	18 Jun 2024	01 Aug 2024	0.6 现金
04 Apr 2024	01 Mar 2024	01 May 2024	0.6 现金
04 Jan 2024	06 Dec 2023	01 Feb 2024	0.6 现金
05 Oct 2023	20 Sep 2023	01 Nov 2023	0.57 现金
06 Jul 2023	14 Jun 2023	01 Aug 2023	0.57 现金
06 Apr 2023	03 Mar 2023	01 May 2023	0.57 现金
05 Jan 2023	08 Dec 2022	01 Feb 2023	0.57 现金
06 Oct 2022	14 Sep 2022	01 Nov 2022	0.54 现金
30 Jun 2022	15 Jun 2022	01 Aug 2022	0.54 现金
31 Mar 2022	01 Mar 2022	02 May 2022	0.54 现金
06 Jan 2022	13 Dec 2021	01 Feb 2022	0.54 现金
30 Sep 2021	09 Sep 2021	01 Nov 2021	0.49 现金
01 Jul 2021	17 Jun 2021	02 Aug 2021	0.49 现金
31 Mar 2021	01 Mar 2021	03 May 2021	0.49 现金
31 Dec 2020	10 Dec 2020	01 Feb 2021	0.49 现金
01 Oct 2020	10 Sep 2020	02 Nov 2020	0.45 现金
02 Jul 2020	11 Jun 2020	03 Aug 2020	0.45 现金
02 Apr 2020	02 Mar 2020	01 May 2020	0.45 现金
02 Jan 2020	06 Dec 2019	03 Feb 2020	0.45 现金
03 Oct 2019	12 Sep 2019	01 Nov 2019	0.41 现金
03 Jul 2019	14 Jun 2019	01 Aug 2019	0.41 现金
04 Apr 2019	08 Mar 2019	01 May 2019	0.41 现金
03 Jan 2019	07 Dec 2018	01 Feb 2019	0.41 现金
04 Oct 2018	13 Sep 2018	01 Nov 2018	0.4 现金
05 Jul 2018	15 Jun 2018	01 Aug 2018	0.4 现金
05 Apr 2018	01 Mar 2018	01 May 2018	0.4 现金
04 Jan 2018	07 Dec 2017	01 Feb 2018	0.4 现金
05 Oct 2017	13 Sep 2017	01 Nov 2017	0.39 现金
05 Jul 2017	13 Jun 2017	01 Aug 2017	0.39 现金
05 Apr 2017	02 Mar 2017	01 May 2017	0.39 现金
04 Jan 2017	08 Dec 2016	01 Feb 2017	0.39 现金
05 Oct 2016	03 Aug 2016	01 Nov 2016	0.38 现金
29 Jun 2016	07 Jun 2016	01 Aug 2016	0.38 现金
30 Mar 2016	03 Mar 2016	02 May 2016	0.38 现金
30 Dec 2015	08 Dec 2015	01 Feb 2016	0.38 现金
30 Sep 2015	17 Sep 2015	02 Nov 2015	0.37 现金
01 Jul 2015	16 Jun 2015	03 Aug 2015	0.37 现金
01 Apr 2015	02 Mar 2015	01 May 2015	0.37 现金
30 Dec 2014	09 Dec 2014	02 Feb 2015	0.37 现金
01 Oct 2014	16 Sep 2014	03 Nov 2014	0.36 现金
01 Jul 2014	17 Jun 2014	01 Aug 2014	0.36 现金
02 Apr 2014	03 Mar 2014	01 May 2014	0.36 现金
31 Dec 2013	19 Dec 2013	03 Feb 2014	0.36 现金
02 Oct 2013	17 Sep 2013	01 Nov 2013	0.35 现金
02 Jul 2013	19 Jun 2013	01 Aug 2013	0.35 现金
显示更多

每年股息收益率

年份	每年总股息 ($)	频率/年份	收益率 %
2025	0.620	1	1.15
2024	2.40	4	4.24
2023	2.28	4	4.44
2022	2.16	4	3.00
2021	1.96	4	3.14
2020	1.80	4	2.90
2019	1.64	4	2.56
2018	1.60	4	3.08
2017	1.56	4	2.55
2016	1.52	4	2.60
2015	1.48	4	2.15
2014	1.44	4	2.44
2013	0.700	2	1.32
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

请登录以添加到您的群组

AI 建议策略模板

自定义的价格提醒

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

请登录以添加到您的群组

已实现利润	-
未实现利润	-
收到股息 2026	-
利润总额	-
平均回报	-
数量(购买)	-
平均价格(购买)	-
数量(卖出)	-
平均价格(卖出)	-

请登录以添加到您的群组

没有符合您标准的股票

营业毛利率	11.38%
营业利益率 (TTM)	31.57%
稀释每股收益 (EPS TTM)	2.68
季度收入增长率 (YOY)	-5.60%
季度盈利增长率 (YOY)	-95.90%

总债务/股东权益 (D/E MRQ)	293.85%
流动比率 (MRQ)	1.28
营业现金流 (OCF TTM)	14.31 B
杠杆自由现金流 (LFCF TTM)	13.93 B

资产报酬率 (ROA TTM)	7.24%
股东权益报酬率 (ROE TTM)	31.99%

安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)